Bladder Cancer - Results from #380

Tumor location at trans-urethral resection is predictive of ipsilateral pelvic lymph-nodal metastases in patients undergoing radical cystectomy for bladder cancer. October 16, 2024

The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (CISTO) study: Lessons learned about management and patient enrollment in a large, pragmatic, patient-centered trial. October 16, 2024

Transition in Quality Of Life Among Older Patients With Bladder Cancer and Its Association With Treatment: A Clustering Approach October 15, 2024

Oncologic outcomes of pelvic organ-preserving radical cystectomy vs. Standard radical cystectomy: A systematic review and meta-analysis. October 15, 2024

VI-RADS followed by Photodynamic Transurethral Resection of Non-Muscle-Invasive Bladder Cancer vs White-Light Conventional and Second-resection: the 'CUT-less' Randomised Trial Protocol. October 15, 2024

Survival Outcomes in Patients With Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of Cycles. October 14, 2024

Strategies to Improve Clinical Outcomes and Patient Experience Undergoing Transurethral Resection of Bladder Tumor. October 14, 2024

Analysis of the Application of the Micrometric Substaging System to Predict Recurrence and Progression in a Cohort of Patients with pT1 High-Grade Non-Muscle Invasive Bladder Cancer. October 14, 2024

Predicting response to intravesical BCG in high-risk non-muscle invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12 center cohort. October 11, 2024

Novel intravesical therapies and delivery systems for the management of bladder cancer. October 11, 2024

Perioperative Complications and In-Hospital Mortality in Paraplegic Radical Cystectomy Patients. October 10, 2024

Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer. October 10, 2024

Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial. October 10, 2024

Management options for node-positive muscle-invasive bladder cancer. October 9, 2024

Prognostic Impact of Bone Metastasis in Patients With Metastatic Urothelial Carcinoma Treated With Durvalumab With or Without Tremelimumab in the DANUBE Study. October 9, 2024

A Single Institution Experience in the Management of Localized Neuroendocrine Carcinoma of the Bladder. October 9, 2024

FGFR Inhibition in Urothelial Carcinoma. October 9, 2024

Treatment Preferences and Tradeoffs Among Patients with Locally Advanced or Metastatic Urothelial Carcinoma - Expert Commentary October 8, 2024

Survival Rates in Trimodal Therapy Versus Radiotherapy in Urothelial Carcinoma of Urinary Bladder. October 7, 2024

The genomic and transcriptomic landscape of metastastic urothelial cancer. October 7, 2024

Page 20 of 535